Literature DB >> 19719752

B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ß1/smad7 pathway in vivo and in vitro.

Jian-Gui He1, Yi-Li Chen, Bai-Li Chen, Yi-Yi Huang, Feng-Juan Yao, Sheng-Long Chen, Yu-Gang Dong.   

Abstract

1. Previously, we showed that long-term treatment of rats after myocardial infarction (MI) with B-type natriuretic peptide (BNP) prevented ventricular remodelling. However, it is unclear whether long-term BNP treatment affects cardiac hypertrophy and, if so, its mechanism of action. In the present study, we investigated the effects of long-term BNP treatment on cardiac hypertrophy and the molecular mechanisms involved. 2. Cardiac hypertrophy was established in rats by ligation of the left anterior descending coronary artery. After treatment with BNP (5 or 15 microg/kg per day) for 8 weeks, indices of cardiac hypertrophy were determined. In separate in vitro experiments, cardiomyocyte hypertrophy was induced by treatment of cardiomyocytes with 10(-6) mol/L angiotensin (Ang) II for 48 h and cell surface area and [(3)H] incorporation were measured. Transforming growth factor (TGF)-beta1 and smad7 mRNA and protein expression in vivo and in vitro were detected using reverse transcription-polymerase chain reaction and western blotting. 3. Long-term BNP treatment dose-dependently attenuated cardiac hypertrophy and improved cardiac function in rats after MI. Furthermore, BNP attenuated the upregulation of TGF-beta1 and downregulation of smad7 mRNA and protein expression. The in vitro experiments further proved that BNP inhibited cardiac hypertrophy and changes in the TGF-beta1/smad7 pathway, which were completely blocked by the cyclic GMP-dependent protein kinase (PKG) inhibitor, KT5823 (cells were treated with 10(-6) mol/L KT5823 for 48 h). 4. The results of the present study demonstrate that long-term treatment of rats with BNP dose-dependently attenuates cardiac hypertrophy and that this is associated with downregulation of TGF-beta1 and upregulation of smad7 via PKG signalling. Long-term BNP treatment may be a new therapeutic strategy to prevent cardiac hypertrophy and progression to heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719752     DOI: 10.1111/j.1440-1681.2009.05281.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

Review 1.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

2.  Inhibitory effect of tanshinone II A on TGF II-β1-induced cardiac fibrosis.

Authors:  Daixing Zhou; Zhihui Li; Liwei Zhang; Chengye Zhan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

3.  Hyaluronan esters drive Smad gene expression and signaling enhancing cardiogenesis in mouse embryonic and human mesenchymal stem cells.

Authors:  Margherita Maioli; Sara Santaniello; Andrea Montella; Pasquale Bandiera; Silvia Cantoni; Claudia Cavallini; Francesca Bianchi; Vincenzo Lionetti; Flavio Rizzolio; Irene Marchesi; Luigi Bagella; Carlo Ventura
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

4.  Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner.

Authors:  Elangovan Vellaichamy; Subhankar Das; Umadevi Subramanian; Nobuyo Maeda; Kailash N Pandey
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

Review 5.  Aldosterone mediates cardiac fibrosis in the setting of hypertension.

Authors:  Feriel Azibani; Loubina Fazal; Christos Chatziantoniou; Jane-Lise Samuel; Claude Delcayre
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

6.  Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction.

Authors:  S Jeson Sangaralingham; John C Burnett; Paul M McKie; John A Schirger; Horng H Chen
Journal:  J Card Fail       Date:  2013-08       Impact factor: 5.712

7.  α-Lipoic acid exerts a primary prevention for the cardiac dysfunction in aortocaval fistula-created rat hearts.

Authors:  Daisuke Kurumazuka; Kento Kitada; Ryosuke Tanaka; Tatsuhiko Mori; Mamoru Ohkita; Masanori Takaoka; Yasuo Matsumura
Journal:  Heliyon       Date:  2019-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.